Summary

Overview
Global Atypical Hemolytic Uremic Syndrome Treatment Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period 2023-2030.
Atypical hemolytic uremic syndrome (aHUS) is a potentially life-threatening condition that causes small blood clots and organ damage. It’s often caused by a genetic mutation that affects the immune system. It is a very rare genetic disease that causes tiny blood clots to form in your blood vessels, blocking blood flow to important organs. aHUS can cause kidney failure, heart disease, and other serious health problems.
The atypical hemolytic uremic syndrome can be diagnosed with several tests that include complete blood count (CBC) and kidney function tests, genetic testing, stool tests, kidney biopsy and others.
Market Dynamics: Drivers & Restraints
Increase in the availability of treatments
Market expansion is anticipated to be driven by the growing number of treatment alternatives being introduced and the rising level of patient awareness. The fundamental causes of aHUS, such as complement dysregulation, are the focus of recently developed therapeutics.
For those suffering from aHUS, these therapies provide novel avenues for treatment. Numerous nations are promoting research on uncommon diseases, such as aHUS, through scientific initiatives. Patients, caregivers, and medical professionals are becoming increasingly aware of aHUS as more is known about the condition. Patient outcomes are being improved by the early diagnosis and treatment of aHUS brought about by this greater knowledge.
Restraint
High cost of the treatment
The cost of aHUS treatment can be very high, which can limit access to care for some patients. The high cost is due to the complexity of the disease, the need for specialized treatment, and the relatively low patient population. Thus, the above factors are expected to hinder the market growth.
Segment Analysis
The global atypical hemolytic uremic syndrome treatment market is segmented based on treatment type, end-user, and region.
Venous Stents segment accounted for 56.3% of the market share
Atypical hemolytic uremic syndrome (aHUS) is caused by dysregulation of the complement system, leading to complement overactivation. Drugs segment holds a dominant position over other types of treatments. This is due to their safety and efficiency in the treatment of the disease.
Eculizumab is a newly developed biologic that blocks the terminal complement pathway and has been successfully used in the treatment of aHUS. Eculizumab (Soliris), the only approved treatment for aHUS,15, 16 is a humanized monoclonal antibody that binds with high affinity to the human C5 complement protein and blocks the formation of proinflammatory C5a and lytic C5b.
Ravulizumab is approved for the treatment of atypical hemolytic uraemic syndrome (aHUS) in several countries, including the United States and the European Union. Ravulizumab was re-engineered from eculizumab to have a longer terminal elimination half-life, resulting in a more convenient maintenance dose regimen of once every 4-8 weeks versus once every 2-3 weeks for eculizumab. Thus, the above factors are expected to hold the segment in the dominant position.
Geographical Analysis
North America is expected to hold a significant position in the global atypical hemolytic uremic syndrome treatment market share
North America is expected to hold a dominant position in the market share. In comparison to other locations, North America has a comparatively high frequency of aHUS, which raises the need for aHUS treatment. New treatments and cures for aHUS have been developed as a result of North America's long history of innovation and technology developments in the healthcare industry. The area also boasts a thriving healthcare sector with cutting-edge medical facilities and highly qualified medical personnel, all of which improve the standard of care for patients with aHUS.
Governments in North America are taking steps to promote research into rare diseases, including aHUS, and this support is driving the development of new therapies and improving access to existing treatments. There is growing awareness of aHUS among patients, caregivers, and healthcare professionals in North America, leading to earlier diagnosis and treatment of the disease.
COVID-19 Impact Analysis
COVID-19 has had a significant impact on the growth of the market. The delayed approvals and launches have caused the lack of availability of drugs to the patients. The companies have shifted their focus towards the manufacturing of COVID-19 medicine. The supply chains have been interrupted due to the implementation of the lockdown.
Market Segmentation
By Treatment Type
• Drug Type
o Eculizumab
o Ravulizumab
• Procedure
o Plasma Therapy
o Dialysis
o Kidney Transplant
By End-User
• Hospital
• Specialty Clinics
• Ambulatory Surgical Centers
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The leading companies with a significant market share include Alexion Pharmaceuticals, Inc., Novartis AG, AstraZeneca Plc, GNHIndia, Omeros Corporation, Chugai Pharmaceutical Co., Ltd., and Bio-Rad Laboratories, Inc. and among others. among others
Why Purchase the Report?
• To visualize the global atypical hemolytic uremic syndrome treatment market segmentation based on treatment type, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of atypical hemolytic uremic syndrome treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global atypical hemolytic uremic syndrome treatment market report would provide approximately 47 tables, 48 figures, and 176 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Treatment Type
3.2. Snippet by End-User
3.3. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increase in the availability of treatments
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. High cost of the treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. Treatment Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.1.2. Market Attractiveness Index, By Treatment Type
7.2. Drug Type
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Eculizumab
7.2.4. Ravulizumab
7.3. Procedure
7.3.1. Plasma Therapy
7.3.2. Dialysis
7.3.3. Kidney transplant
8. By End-User
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.1.2. Market Attractiveness Index, By End-User
8.2. Hospital
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Specialty Clinics
8.4. Ambulatory Surgical Centers
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.5.1. U.S.
9.2.5.2. Canada
9.2.5.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.5.1. Germany
9.3.5.2. UK
9.3.5.3. France
9.3.5.4. Italy
9.3.5.5. Spain
9.3.5.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.5.1. Brazil
9.4.5.2. Argentina
9.4.5.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.5.1. China
9.5.5.2. India
9.5.5.3. Japan
9.5.5.4. Australia
9.5.5.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Alexion Pharmaceuticals, Inc. *
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Novartis AG
11.3. AstraZeneca Plc
11.4. GNHIndia
11.5. Omeros Corporation
11.6. Chugai Pharmaceutical Co., Ltd.
11.7. Bio-Rad Laboratories, Inc.
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us